|
1
|
Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
|
J Clin Oncol
|
1996
|
2.61
|
|
2
|
Dermatofibrosarcoma protuberans: treatment and prognosis.
|
Eur J Surg Oncol
|
1992
|
1.87
|
|
3
|
Anatomy and physiology of lymphatic drainage of the breast from the perspective of sentinel node biopsy.
|
J Am Coll Surg
|
2001
|
1.79
|
|
4
|
Reliability of sentinel lymph node biopsy for staging melanoma.
|
Br J Surg
|
2000
|
1.71
|
|
5
|
Positive iliac and obturator nodes in melanoma: survival and prognostic factors.
|
Ann Surg Oncol
|
1999
|
1.55
|
|
6
|
Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
|
J Am Coll Surg
|
1996
|
1.54
|
|
7
|
Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
|
Ann Surg
|
1996
|
1.51
|
|
8
|
Lymph node metastasis from melanoma with an unknown primary site.
|
Br J Surg
|
1990
|
1.49
|
|
9
|
Clear cell sarcoma (malignant melanoma) of soft parts: A clinicopathologic study of 30 cases.
|
Cancer
|
1999
|
1.46
|
|
10
|
[Identification of the sentinel node in patients with breast carcinoma].
|
Ned Tijdschr Geneeskd
|
1996
|
1.42
|
|
11
|
Evaluation of mammary lymphoscintigraphy by a single intratumoral injection for sentinel node identification.
|
J Nucl Med
|
2000
|
1.25
|
|
12
|
Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan.
|
Surgery
|
1994
|
1.23
|
|
13
|
Frozen section investigation of the sentinel node in malignant melanoma and breast cancer.
|
Ann Surg Oncol
|
2001
|
1.19
|
|
14
|
The definition of a sentinel node.
|
Ann Surg Oncol
|
2001
|
1.15
|
|
15
|
Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593.
|
J Clin Oncol
|
1998
|
1.14
|
|
16
|
Localizing the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye.
|
Ann Surg Oncol
|
1997
|
1.13
|
|
17
|
Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics.
|
Eur J Surg Oncol
|
1988
|
1.10
|
|
18
|
Surgery for melanoma metastatic to the gastrointestinal tract.
|
Br J Surg
|
1990
|
1.06
|
|
19
|
History of sentinel node and validation of the technique.
|
Breast Cancer Res
|
2001
|
1.05
|
|
20
|
Single intralesional tracer dose for radio-guided excision of clinically occult breast cancer and sentinel node.
|
Ann Surg Oncol
|
2001
|
1.04
|
|
21
|
VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha.
|
J Pathol
|
1995
|
0.98
|
|
22
|
Vascular complications of isolated limb perfusion.
|
Eur J Surg Oncol
|
1998
|
0.97
|
|
23
|
Altered lymphatic drainage after lymphadenectomy or radiotherapy of the axilla in patients with breast cancer.
|
Br J Surg
|
1996
|
0.97
|
|
24
|
Lymphatic mapping and sentinel lymph node biopsy in breast cancer.
|
Eur J Nucl Med
|
1999
|
0.97
|
|
25
|
Reliability of lymphoscintigraphy in indicating the number of sentinel nodes in melanoma patients.
|
Ann Surg Oncol
|
2000
|
0.96
|
|
26
|
Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions.
|
Arch Surg
|
1995
|
0.96
|
|
27
|
Sentinel node biopsy for melanoma in the head and neck region.
|
Head Neck
|
2000
|
0.96
|
|
28
|
Sentinel nodes outside lymph node basins in patients with melanoma.
|
Br J Surg
|
2001
|
0.93
|
|
29
|
Severe acute regional toxicity after normothermic or 'mild' hyperthermic isolated limb perfusion with melphalan for melanoma.
|
Melanoma Res
|
1995
|
0.93
|
|
30
|
Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.
|
Br J Cancer
|
1994
|
0.91
|
|
31
|
Thirty-five years of isolated limb perfusion for melanoma: indications and results.
|
Br J Surg
|
1996
|
0.90
|
|
32
|
Identification and biopsy of the sentinel lymph node in breast cancer.
|
Eur J Surg Oncol
|
1998
|
0.90
|
|
33
|
Epithelioid sarcoma.
|
Eur J Surg Oncol
|
1989
|
0.90
|
|
34
|
Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma.
|
J Am Coll Surg
|
1999
|
0.90
|
|
35
|
Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities.
|
Cancer
|
1989
|
0.90
|
|
36
|
Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
|
Ann Surg Oncol
|
1999
|
0.89
|
|
37
|
Lymphatic mapping with intralesional tracer administration in breast carcinoma patients.
|
Cancer
|
2000
|
0.89
|
|
38
|
Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors.
|
J Surg Oncol
|
1997
|
0.88
|
|
39
|
Toxicity and morbidity of isolated limb perfusion.
|
Semin Surg Oncol
|
1998
|
0.88
|
|
40
|
Improved sentinel node visualization in breast cancer by optimizing the colloid particle concentration and tracer dosage.
|
Nucl Med Commun
|
2001
|
0.87
|
|
41
|
Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan.
|
Eur J Surg Oncol
|
1999
|
0.86
|
|
42
|
Lymph node metastases in the neck and parotid gland from an unknown primary melanoma.
|
Clin Otolaryngol Allied Sci
|
1994
|
0.86
|
|
43
|
Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study.
|
Melanoma Res
|
1994
|
0.86
|
|
44
|
Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study.
|
Arch Surg
|
1999
|
0.85
|
|
45
|
Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities.
|
Am J Surg
|
1994
|
0.85
|
|
46
|
Normothermic isolation perfusion with melphalan for advanced melanoma of the limbs.
|
Anticancer Res
|
1987
|
0.85
|
|
47
|
Isolated limb perfusion with high-dose tumor necrosis factor-alpha for locally advanced extremity soft tissue sarcomas.
|
Cancer Treat Res
|
1997
|
0.85
|
|
48
|
A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities.
|
Eur J Cancer
|
1995
|
0.85
|
|
49
|
Is lymphatic mapping in breast cancer adequate and safe?
|
World J Surg
|
2001
|
0.84
|
|
50
|
Technique of sentinel node biopsy in breast cancer.
|
Eur J Surg Oncol
|
1998
|
0.84
|
|
51
|
Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
|
Eur J Surg Oncol
|
2001
|
0.84
|
|
52
|
Lymphoscintigraphy in oncology: a rediscovered challenge.
|
Eur J Nucl Med
|
1999
|
0.83
|
|
53
|
Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion.
|
J Am Coll Surg
|
1994
|
0.83
|
|
54
|
Systemic leakage during isolated limb perfusion for melanoma.
|
Br J Surg
|
1993
|
0.83
|
|
55
|
Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone.
|
Cancer Chemother Pharmacol
|
1992
|
0.83
|
|
56
|
False negative sentinel node procedure established through palpation of the biopsy wound.
|
Eur J Surg Oncol
|
2000
|
0.82
|
|
57
|
Isolated limb perfusion in primary and recurrent melanoma: indications and results.
|
Semin Surg Oncol
|
1998
|
0.82
|
|
58
|
Reproducibility of lymphoscintigraphy for lymphatic mapping in cutaneous melanoma.
|
J Nucl Med
|
1996
|
0.82
|
|
59
|
A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb.
|
Cancer
|
1993
|
0.81
|
|
60
|
Sensitivity of sentinel node biopsy in melanoma.
|
J Surg Oncol
|
2001
|
0.81
|
|
61
|
Validation of gamma probe detection of the sentinel node in melanoma.
|
J Nucl Med
|
1997
|
0.81
|
|
62
|
Low risk of locoregional recurrence of primary breast carcinoma after treatment with a modification of the Halsted radical mastectomy and selective use of radiotherapy.
|
Cancer
|
1999
|
0.81
|
|
63
|
Results of radical dissection of the groin in patients with stage II melanoma and histologically proved metastases of the iliac or obturator lymph nodes, or both.
|
Surg Gynecol Obstet
|
1988
|
0.81
|
|
64
|
[Characteristics of patients with recurrence of primary melanoma at least 10 years following surgical treatment].
|
Ned Tijdschr Geneeskd
|
1994
|
0.80
|
|
65
|
Is there an indication for a double perfusion schedule with melphalan for patients with recurrent melanoma of the limbs?
|
Melanoma Res
|
1994
|
0.80
|
|
66
|
Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas.
|
Semin Oncol
|
1997
|
0.79
|
|
67
|
[Revised consensus melanoma of the skin].
|
Ned Tijdschr Geneeskd
|
1990
|
0.79
|
|
68
|
Results of regional isolated perfusion for locally inoperable melanoma of the limbs.
|
Melanoma Res
|
1994
|
0.78
|
|
69
|
The value of Cloquet's node in predicting melanoma nodal metastases in the pelvic lymph node basin.
|
Ann Surg Oncol
|
2001
|
0.78
|
|
70
|
Comparison between the use of whole blood versus a diluted perfusate in regional isolated perfusion by continuous monitoring of transcutaneous oxygen tension: a pilot study.
|
J Invest Surg
|
1994
|
0.78
|
|
71
|
Systemic toxicity after isolated limb perfusion with melphalan for melanoma.
|
Eur J Surg Oncol
|
1996
|
0.78
|
|
72
|
To perfuse or not to perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5 mm or greater.
|
J Clin Oncol
|
1988
|
0.78
|
|
73
|
Physiological implications of hyperbaric oxygen tensions in isolated limb perfusion using melphalan: a pilot study.
|
Eur Surg Res
|
1996
|
0.78
|
|
74
|
Improved staging of breast cancer through lymphatic mapping and sentinel node biopsy.
|
Eur J Surg Oncol
|
1998
|
0.78
|
|
75
|
Controversies concerning adjuvant regional isolated perfusion for stage I melanoma of the extremities.
|
World J Surg
|
1992
|
0.77
|
|
76
|
Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities.
|
Radiother Oncol
|
1998
|
0.77
|
|
77
|
[Alveolar soft tissue sarcoma].
|
Ned Tijdschr Geneeskd
|
1981
|
0.77
|
|
78
|
Value of laboratory tests in monitoring acute regional toxicity after isolated limb perfusion.
|
Ann Surg Oncol
|
1997
|
0.77
|
|
79
|
Hyperthermic isolated limb perfusion for the treatment of soft tissue sarcomas.
|
Semin Surg Oncol
|
1998
|
0.77
|
|
80
|
Report of a symposium on diagnosis and treatment of adult soft tissue sarcomas in the head and neck.
|
Eur J Surg Oncol
|
1995
|
0.77
|
|
81
|
Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma.
|
Melanoma Res
|
1997
|
0.76
|
|
82
|
Modification of human tumour and normal tissue pH during hyperthermic and normothermic antiblastic regional isolation perfusion for malignant melanoma: a pilot study.
|
Int J Hyperthermia
|
1993
|
0.76
|
|
83
|
High tPA-expression in primary melanoma of the limb correlates with good prognosis.
|
Br J Cancer
|
2000
|
0.76
|
|
84
|
Computed tomography for the detection of neck node metastases in melanoma patients.
|
Eur J Surg Oncol
|
1998
|
0.76
|
|
85
|
The Denver type for peritoneovenous shunting of malignant ascites.
|
Surg Gynecol Obstet
|
1986
|
0.75
|
|
86
|
[The role of sentinel node biopsies in the treatment of patients with breast carcinoma].
|
Ned Tijdschr Geneeskd
|
1996
|
0.75
|
|
87
|
Sentinel-node biopsy in breast cancer.
|
Lancet
|
1997
|
0.75
|
|
88
|
The effects of negative regional lymph-node dissection on survival and disease-free interval of patients with stage-I malignant melanoma.
|
Neth J Surg
|
1990
|
0.75
|
|
89
|
[Summary of the guideline 'Sentinel Lymph Node Biopsy for Breast Cancer'].
|
Ned Tijdschr Geneeskd
|
2001
|
0.75
|
|
90
|
Sentinel-node biopsy sampling in breast cancer.
|
Lancet
|
2000
|
0.75
|
|
91
|
Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the limbs.
|
Eur J Surg Oncol
|
1994
|
0.75
|
|
92
|
Lymphatic mapping and selective lymphadenectomy for melanoma: not yet standard therapy.
|
Eur J Surg Oncol
|
1997
|
0.75
|
|
93
|
[Detection of metastatic melanoma in sentinel lymph nodes by means of polymerase chain reaction].
|
Ned Tijdschr Geneeskd
|
1998
|
0.75
|
|
94
|
Massive hemoperitoneum from rupture of richly vascularized benign liver tumours in women on oral contraceptives.
|
Neth J Surg
|
1984
|
0.75
|
|
95
|
[Chronic subphrenic abscess].
|
Ned Tijdschr Geneeskd
|
1980
|
0.75
|
|
96
|
Report of a symposium on: diagnosis and treatment of cutaneous head and neck melanoma.
|
Eur J Surg Oncol
|
1994
|
0.75
|
|
97
|
Rationale for different approaches to combined melphalan and hyperthermia in regional isolated perfusion.
|
Eur J Cancer
|
1997
|
0.75
|
|
98
|
The role of regional isolated perfusion in the eradication of melanoma micrometastases in the inguinal nodes: a comparison between an iliac and femoral perfusion procedure.
|
Melanoma Res
|
1992
|
0.75
|
|
99
|
[Hydrothorax in ascites and its treatment with a peritoneovenous shunt].
|
Ned Tijdschr Geneeskd
|
1984
|
0.75
|
|
100
|
Regional isolated perfusion with melphalan for patients with subungual melanoma.
|
Eur J Surg Oncol
|
1993
|
0.75
|
|
101
|
Temperature distribution and pH changes during hyperthermic regional isolation perfusion.
|
Eur J Cancer Clin Oncol
|
1989
|
0.75
|
|
102
|
[Pain in the right upper quadrant in young women: the Fitz-Hugh-Curtis syndrome].
|
Ned Tijdschr Geneeskd
|
1986
|
0.75
|
|
103
|
The Netherlands Cancer Institute 75 years; strategies in the surgical department.
|
Eur J Surg Oncol
|
1988
|
0.75
|
|
104
|
Malignant cutaneous melanoma associated with neurofibromatosis in two sisters from a family with familial atypical multiple mole melanoma syndrome. Case reports and review of the literature.
|
Cancer
|
1993
|
0.75
|
|
105
|
[The Hickman central venous catheter for the treatment of patients with cancer].
|
Ned Tijdschr Geneeskd
|
1985
|
0.75
|
|
106
|
Isolated limb perfusion: the European experience.
|
Surg Oncol Clin N Am
|
2001
|
0.75
|
|
107
|
Technique of lymphatic mapping and sentinel node biopsy for melanoma.
|
Eur J Surg Oncol
|
1998
|
0.75
|
|
108
|
Temporary vascular occlusion and glucose: effects on tumour and normal tissue pH in animal experiments.
|
Int J Hyperthermia
|
1996
|
0.75
|
|
109
|
Cervical lymph-node metastasis from cutaneous melanoma of the head and neck: a search for prognostic factors.
|
Eur J Surg Oncol
|
1998
|
0.75
|
|
110
|
Carbon dioxide laser for cutaneous melanoma metastases: indications and limitations.
|
Eur J Surg Oncol
|
1997
|
0.75
|
|
111
|
Adjuvant regional isolated perfusion with melphalan for patients with Clark V melanoma of the extremities.
|
J Surg Oncol
|
1993
|
0.75
|
|
112
|
[Origin of bacteria in bile; a prospective bacteriological study].
|
Ned Tijdschr Geneeskd
|
1980
|
0.75
|
|
113
|
Prevention of seroma following axillary lymph node dissection or radical mastectomy; ineffectiveness of fibrin glue sealing technique.
|
Neth J Surg
|
1987
|
0.75
|
|
114
|
Contralateral inguinal lymph node metastasis in patients with melanoma of the lower extremities.
|
Br J Surg
|
1989
|
0.75
|
|
115
|
[Loa loa: "the eye worm"].
|
Ned Tijdschr Geneeskd
|
1981
|
0.75
|
|
116
|
[Pneumothorax in lung carcinoma].
|
Ned Tijdschr Geneeskd
|
1979
|
0.75
|